On Wednesday, National Retail Properties, Inc. (NYSE:NNN)’s shares inclined 2.46% to $35.03.
National Retail Properties, Inc. (NNN), a real estate investment trust, declared its operating results for the quarter and six months ended June 30, 2015. Highlights comprise:
Second Quarter 2015 Highlights:
- FFO per share and Recurring FFO per share raised 10.0% over preceding year results
- AFFO per share raised 9.8% over preceding year results
- Portfolio occupancy is 98.8% at June 30, 2015, compriseent with March 31, 2015, and 98.6% at December 31, 2014
- Invested $147.8 million in 37 properties with an aggregate 669,000 square feet of gross leasable area at an initial cash yield of 7.1%
- Sold three properties for $2.2 million producing $30,000 of gains on sales
- Raised $38.7 million in net proceeds from the issuance of 983,317 common shares
National Retail Properties, Inc. is a publicly owned equity real estate investment trust. The firm acquires, owns, manages, and develops retail properties in the United States. It provides complete turn-key and built-to-suit development services counting market analysis, site selection and acquisition, entitlements, permitting, and construction administration.
Raytheon Company (NYSE:RTN)’s shares gained 3.07% to $103.62.
Raytheon Company (RTN) declared net sales for the second quarter 2015 were $5.8 billion contrast to $5.7 billion in the second quarter 2014. Second quarter 2015 EPS from ongoing operations was $1.65 contrast to $1.59 in the second quarter 2014. Second quarter 2015 EPS from ongoing operations comprised of a favorable FAS/CAS Adjustment of $0.10 contrast to a favorable FAS/CAS Adjustment of $0.18 in the second quarter 2014. In addition, second quarter 2015 EPS from ongoing operations comprised of, as predictable, a $0.29 favorable impact from a tax settlement.
The Company had bookings of $7.6 billion in the second quarter 2015, resulting in a book-to-bill ratio of 1.30. In the second quarter 2014, bookings were $6.8 billion. Year-to-date 2015 bookings were $12.1 billion, resulting in a book-to-bill ratio of 1.08. Year-to-date 2014 bookings were $11.1 billion.
Raytheon Company develops integrated products, services, and solutions in the areas of sensing; effects; command, control, communications, and intelligence; mission support; and cyber and information security worldwide. It operates in four segments: Integrated Defense Systems (IDS); Intelligence, Information, and Services (IIS); Missile Systems (MS); and Space and Airborne Systems (SAS). The IDS segment provides integrated air and missile defense; radar solutions; naval combat and ship electronic systems; command, control, communications, computers, and intelligence solutions; and air traffic administration systems.
At the end of Wednesday’s trade, Accuray Incorporated (NASDAQ:ARAY)‘s shares dipped -0.77% to $6.42.
Accuray Incorporated (ARAY) declared it has received a multi-system order from 21st Century Oncology for one CyberKnife® M6™ and four TomoHDA™ Systems. These are the latest generation CyberKnife and TomoTherapy Systems, and are used worldwide to provide extremely precise radiation treatments for cancerous and non-cancerous tumors throughout the body. The TomoTherapy Systems will replace conventional linear accelerators in single vault freestanding centers, reinforcing the TomoTherapy’s value as a mainstream radiation therapy device. Accuray booked the order in its first fiscal quarter of 2016.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, in addition to enables delivery of precise, high dose radiation while patients breathe normally.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), ended its Wednesday’s trading session with 5.75% gain, and closed at $128.10.
BioMarin Pharmaceutical Inc. (BMRN) declared that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for drisapersen, a potential treatment for patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 51 skipping treatment. The FDA has formerly granted drisapersen Orphan and Fast Track Status, Breakthrough Therapy Designation, in addition to Precedingity Review status, which is designated to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, counting drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally accessible poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
